溶瘤病毒疗法需要临床试验，而不是准入项目。
Oncolytic virotherapy needs trials, not access programs.
机构信息
The Institute of Cancer Research, Targeted Therapy Team, London, United Kingdom.
出版信息
Clin Cancer Res. 2013 May 15;19(10):2595-7. doi: 10.1158/1078-0432.CCR-13-0571. Epub 2013 Apr 2.
Abstract
Oncolytic virotherapy is a novel treatment for cancer that exerts direct lytic and indirect immune-mediated antitumor effects. A Finnish research team has reported on an advanced therapy access program for oncolytic adenovirus. The strengths and weaknesses of this approach are highlighted with a view to informing future study conduct.
摘要
溶瘤病毒治疗是一种治疗癌症的新方法，可发挥直接溶瘤和间接免疫介导的抗肿瘤作用。芬兰的一个研究团队报告了溶瘤腺病毒的先进治疗准入计划。本文旨在为未来的研究提供信息，强调了这种方法的优缺点。
Zotero 插件